NewEdge Wealth LLC Purchases 22,811 Shares of Healthpeak Properties, Inc. $DOC

NewEdge Wealth LLC boosted its holdings in Healthpeak Properties, Inc. (NYSE:DOC) by 65.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 57,418 shares of the real estate investment trust’s stock after purchasing an additional 22,811 shares during the quarter. NewEdge Wealth LLC’s holdings in Healthpeak Properties were worth $943,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of DOC. Fiduciary Trust Co grew its holdings in shares of Healthpeak Properties by 4.9% during the third quarter. Fiduciary Trust Co now owns 13,807 shares of the real estate investment trust’s stock valued at $264,000 after buying an additional 644 shares during the last quarter. Patton Fund Management Inc. raised its holdings in shares of Healthpeak Properties by 5.2% in the 4th quarter. Patton Fund Management Inc. now owns 13,002 shares of the real estate investment trust’s stock worth $209,000 after acquiring an additional 648 shares during the last quarter. Quadrant Capital Group LLC raised its holdings in shares of Healthpeak Properties by 1.9% in the 3rd quarter. Quadrant Capital Group LLC now owns 37,650 shares of the real estate investment trust’s stock worth $721,000 after acquiring an additional 718 shares during the last quarter. Quantum Portfolio Management LLC lifted its position in Healthpeak Properties by 2.5% in the 1st quarter. Quantum Portfolio Management LLC now owns 29,372 shares of the real estate investment trust’s stock valued at $483,000 after acquiring an additional 728 shares in the last quarter. Finally, Intrua Financial LLC boosted its stake in Healthpeak Properties by 1.1% during the 1st quarter. Intrua Financial LLC now owns 66,702 shares of the real estate investment trust’s stock valued at $1,096,000 after purchasing an additional 744 shares during the last quarter. Institutional investors own 93.57% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on DOC. JPMorgan Chase & Co. boosted their price objective on Healthpeak Properties from $18.00 to $21.00 and gave the stock a “neutral” rating in a report on Wednesday, June 24th. Royal Bank Of Canada raised their target price on Healthpeak Properties from $20.00 to $21.00 and gave the company an “outperform” rating in a report on Thursday, May 14th. Raymond James Financial initiated coverage on Healthpeak Properties in a report on Wednesday, June 17th. They set a “market perform” rating for the company. Wall Street Zen raised Healthpeak Properties from a “sell” rating to a “hold” rating in a research report on Sunday, May 10th. Finally, UBS Group increased their price target on Healthpeak Properties from $19.00 to $21.50 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Four equities research analysts have rated the stock with a Buy rating and fifteen have given a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $20.62.

Healthpeak Properties Trading Up 1.2%

Shares of DOC stock opened at $22.53 on Tuesday. Healthpeak Properties, Inc. has a 52-week low of $15.70 and a 52-week high of $22.77. The company has a debt-to-equity ratio of 1.15, a quick ratio of 2.96 and a current ratio of 2.96. The company has a 50-day simple moving average of $20.80 and a two-hundred day simple moving average of $18.51. The company has a market capitalization of $15.53 billion, a price-to-earnings ratio of 70.41, a PEG ratio of 3.46 and a beta of 1.02.

Healthpeak Properties (NYSE:DOC) last posted its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 EPS for the quarter, beating the consensus estimate of $0.43 by $0.02. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. The firm had revenue of $752.95 million during the quarter, compared to analyst estimates of $694.59 million. During the same quarter last year, the business posted $0.46 EPS. The company’s revenue for the quarter was up 7.1% on a year-over-year basis. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. Research analysts anticipate that Healthpeak Properties, Inc. will post 1.75 EPS for the current fiscal year.

Healthpeak Properties Dividend Announcement

The firm also recently declared a monthly dividend, which will be paid on Friday, September 25th. Investors of record on Monday, September 14th will be given a dividend of $0.1017 per share. This represents a c) dividend on an annualized basis and a dividend yield of 5.4%. The ex-dividend date of this dividend is Monday, September 14th. Healthpeak Properties’s dividend payout ratio (DPR) is presently 381.25%.

Insider Activity at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of Healthpeak Properties stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $19.45, for a total transaction of $213,736.05. Following the sale, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. This trade represents a 59.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 0.23% of the company’s stock.

About Healthpeak Properties

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.